|
| Sibofimloc |
|
Escherichia |
Adherence |
Phase II trial |
|
| Fluorothiazinon |
|
Acinetobacter
Chlamydia
Klebsiella
Pseudomonas
Salmonella |
Biofilm
TTSS (Type III secretion system)
Biofilm
TTSS (Type III secretion system)
TTSS (SPI-1 encode); TTSS (SPI-2 encode) |
In vivo
In vivo
In vitro
In vivo
Phase II trial |
|
| Zosurabalpin |
|
Acinetobacter |
LPS |
Phase I trial |
|
| N-(2-{(2Z)-2-[1-(1,3-benzodioxol-5-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]hydrazinyl}-2-oxoethyl)pyridine-3-carboxamide |
|
Acinetobacter |
Regulation |
In vivo |
|
| Auranofin |
|
Clostridium |
CDT (Clostridium difficile toxin) |
In vivo |
|
| 3-Methylthio-1,4-diphenyl-1H-1,3,4-triazolium |
|
Escherichia |
Heat-labile toxin (LT) |
In vivo |
|
| 7-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2H-isoquinolin-1-one |
|
Escherichia |
Type 1 fimbriae |
In vivo |
|
| (3R)-5-Oxo-6-(morpholinomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt |
|
Escherichia |
Type 1 fimbriae; P fimbriae |
In vivo |
|
| (3R)-5-Oxo-6-(dimethylaminomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt |
|
Escherichia |
Type 1 fimbriae; P fimbriae |
In vivo |
|
| (3R)-5-Oxo-6-(dimethylaminomethyl)-7-methyl-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt |
|
Escherichia |
Type 1 fimbriae; P fimbriae |
In vivo |
|
| | | |
